Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 79 of 79. Open to participants first (2,630), then studies with results posted, then the rest; newest registration first within each.
- A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289627Phase 2
- Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)CompletedNCT00261365Phase 1/2
- CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior TherapyCompletedNCT00257205Phase 3
- Study of CP-675,206 in Refractory MelanomaCompletedNCT00254579Phase 2
- A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideCompletedNCT00135408Phase 2
- CP-675,206 In Patients With Advanced MelanomaCompletedNCT00086489Phase 2
- Study of MDX-010 in Stage IV Breast CancerCompletedNCT00083278Phase 2
- Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
- Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell CancerCompletedNCT00057889Phase 2
- Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate CancerCompletedNCT00050596Phase 2
- Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic MelanomaCompletedNCT00050102Phase 2
- Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine TherapyCompletedNCT00047164Phase 1
- Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1